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Physiological evidencesuggests that sleepmodulateskidney function.Our
objective was to examine the cross-sectional association between kidney
function and objectively-estimated habitual sleep duration, quality and
timing in a cohort of patients with mild to moderate chronic kidney disease.
This study involved two US clinical centers of the Chronic Renal
Insufficiency Cohort (CRIC) study, including 432 participants in a CRIC
ancillary sleep study. Habitual sleep duration, quality and timing were
measured using wrist actigraphy for 5–7 days. Validated sleep question-
naires assessed subjective sleep quality, daytime sleepiness and risk of
sleep apnea. Kidney function was assessed with the estimated glomerular
filtration rateusing theChronicKidneyDiseaseEpidemiologyCollaboration
equation, and the urinary protein to creatinine ratio. Lower estimated
glomerular filtration rate was associated with shorter sleep duration
(1.1 mL min1 1.73 m2 per hour less sleep, P = 0.03), greater sleep
fragmentation (2.6 mL min1 1.73 m2 per 10% higher fragmentation,
P < 0.001) and later timing of sleep (0.9 mL min1 1.73 m2 per hour
later,P = 0.05). Higher protein to creatinine ratio was also associated with
greater sleep fragmentation (approximately 28% higher per 10% higher
fragmentation, P < 0.001). Subjective sleep quality, sleepiness and
persistent snoring were not associated with estimated glomerular filtration
rate or protein to creatinine ratio. Thus, worse objective sleep quality was
associatedwith lower estimatedglomerular filtration rate andhigherprotein
to creatinine ratio. Shorter sleep duration and later sleep timing were also
associated with lower estimated glomerular filtration rate. Physicians
treating patients with chronic kidney disease should consider inquiring
about sleep and possibly sending for clinical sleep assessment. Longitu-
dinal and interventional trials are needed to understand causal direction.
INTRODUCTION
Over 20 million adults (approximately 10% of the adult US
population) have chronic kidney disease (CKD; Coresh et al.,
2007; Eckardt et al., 2013). Impaired kidney function is
associated with increased risk of cardiovascular disease and
age-adjusted mortality and, as kidney function worsens,
these risks increase (Eckardt et al., 2013; Gansevoort et al.,
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2013). Thus, identification of novel, modifiable risk factors
associated with the progression of CKD would increase our
understanding of the pathophysiology of CKD, and potentially
lead to new therapies to prevent or delay end-stage renal
disease (ESRD) and reduce the health burden associated
with CKD.
One novel risk factor may be inadequate sleep, including
insufficient sleep, poor sleep quality and later sleep timing.
Under normal conditions, sleep profoundly modulates the
key hormones involved in the control of kidney function,
particularly those of the rennin–angiotensin–aldosterone
system, which exhibit large diurnal variations that are
dependent on sleep (Brandenberger et al., 1994; Charloux
et al., 1999; Hurwitz et al., 2004; Turek et al., 2012). Normal
sleep suppresses urinary sodium excretion (Rubin et al.,
1978), and acute total sleep deprivation reduces the normal
nocturnal increases in plasma renin activity (PRA) and
aldosterone (Charloux et al., 2001). Sleep quality, indepen-
dently of sleep duration, may also play an important role in
kidney function because during normal sleep, the rapid eye
movement (REM)–non(N)REM cycle drives a robust ultra-
dian oscillation of PRA and aldosterone (Brandenberger
et al., 1988, 1994). Experimental studies that manipulated
sleep or the circadian system have observed significant
changes in several physiological systems that could affect
kidney function, including increased sympathetic nervous
system activity (Buxton et al., 2010; Spiegel et al., 1999,
2004; Stamatakis and Punjabi, 2010; Tasali et al., 2008),
alterations in the 24-h profiles of growth hormone and
cortisol (Buxton et al., 2010; Spiegel et al., 1999, 2000),
increased blood pressure (Sayk et al., 2010; Scheer et al.,
2009; Tochikubo et al., 1996), and impaired glucose toler-
ance (Buxton et al., 2010; Leproult et al., 2014; Nedeltcheva
et al., 2009; Scheer et al., 2009; Spiegel et al., 1999;
Stamatakis and Punjabi, 2010; Tasali et al., 2008). Given
these established associations between sleep, circadian
alignment and several physiological systems that affect
kidney function, it is possible that habitual sleep patterns
could influence the risk and severity of CKD.
Previous research has found that self-reported habitual
sleep duration is associated with prevalent and incident CKD
(Turek et al., 2012). Studies have found that the prevalence
of kidney disease or renal hyperfiltration was higher in those
reporting short sleep durations as well as in those reporting
long sleep durations compared with those sleeping 7–8 h per
night (Cheungpasitporn et al., 2016; Kim et al., 2017; Lin
et al., 2017; Salifu et al., 2014), although one study only
observed this association in women (Choi et al., 2017).
Further, the incidence of proteinuria was greater among
people reporting shorter sleep duration (≤5 h per night) in a
sample of employees of Osaka University in Japan (Yama-
moto et al., 2012). Finally, a study of Japanese type 2
diabetic patients without CKD found that both self-reported
short and long sleep durations were significantly associated
with higher urinary albumin–creatinine ratios (Ohkuma et al.,
2013). Whether or not sleep characteristics are associated
with kidney function among people who already have kidney
disease remains to be determined.
The aim of the present study was to examine the
association between sleep and kidney function, as
assessed by both the estimated glomerular filtration rate
(eGFR) and the urine protein to creatinine ratio (PCR) in
patients with mild to moderate CKD. Habitual sleep duration,
quality and timing were objectively assessed via actigraphy
and self-reports of sleep quality; daytime sleepiness and
risk of sleep apnea were obtained via questionnaires. Our
hypothesis was that inadequate sleep, defined as shorter
sleep duration, poorer sleep quality, later sleep timing or
greater daytime sleepiness would be associated with worse
kidney function.
MATERIALS AND METHODS
CRIC and HCRIC cohorts
The Chronic Renal Insufficiency Cohort (CRIC) Study is a
prospective observational study of over 3000 subjects with
CKD (Feldman et al., 2003). The CRIC Study was estab-
lished in order to improve our understanding of CKD and its
relationship with cardiovascular disease and other complica-
tions of CKD. At enrollment, participants were aged 21–
74 years, had an eGFR value above 20 mL min1 1.73 m2
and below 50–70 mL min1 1.73 m2, depending on age,
and approximately 50% had type 2 diabetes mellitus.
Exclusion criteria included being institutionalized; having
previously undergone dialysis for longer than 1 month;
having a previous diagnosis of polycystic kidney disease;
having had an organ or bone marrow transplant; having been
on immunosuppressive drugs for kidney disease in the past
6 months; cancer chemotherapy within 2 years; current
participation in another research study including clinical
trials; having New York Heart Association Class III or IV
heart failure, cirrhosis, HIV infection or AIDS, multiple
myeloma or renal cell carcinoma (Yaffe et al., 2010). CRIC
participants were recruited at seven sites across the USA.
This sleep ancillary study recruited subjects from two of these
sites: University of Illinois, Chicago, Illinois, USA; and Case
Western Reserve University, including the University Hospi-
tal, the affiliated MetroHealth System, and Cleveland Clinic,
in Cleveland, Ohio, USA. A second cohort, the Hispanic
CRIC (HCRIC) cohort, was created to increase the number of
Hispanics in the study (Fischer et al., 2011). The inclusion/
exclusion criteria and the clinical evaluations for HCRIC were
identical to CRIC; however, HCRIC involved only one site,
the University of Illinois, Chicago, USA. Participants in the
CRIC and HCRIC studies participated in annual clinical
examinations. We used the clinical data that were obtained
closest to the sleep assessment in our analyses. The interval
between the clinical examination and the sleep assessment
was 21 days on average; 63% of the sample had the two
assessments within 90 days of each other and 92% within
180 days.
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Kidney function was assessed using eGFR and PCR
because of their well-established and complementary roles
in staging CKD and predicting outcomes. Fasting blood
samples were drawn at each clinical examination and serum
creatinine was assayed. A 24-h urine collection was also
collected at each clinical examination, and protein and
creatinine levels were measured. The eGFR
(mL min1 1.73 m2) was calculated using the Chronic
Kidney Disease Epidemiology Collaboration (CKD-EPI)
equation (Levey et al., 2009). This equation includes log
serum creatinine (modelled as a 2-slope linear spline with
sex-specific knots), sex, race and age on the natural scale
(Levey et al., 2009). The urine PCR (mcg mg1) was also
calculated.
Sleep
This study included both objective estimates of habitual sleep
patterns using wrist activity monitoring and subjective esti-
mates of sleep quality and daytime sleepiness. We also used
a validated screening instrument to identify participants likely
to have sleep apnea due to snoring symptoms.
Participants wore a wrist activity monitor (Actiwatch-16 in
CRIC and Actiwatch-2 in HCRIC, Philips/Respironics, Bend
OR, USA) continuously for 5–7 days to estimate habitual
sleep duration and quality (n = 405). Participants in the CRIC
Study were also asked to wear an activity monitor (Actiwatch-
64, Philips/Respironics, Bend OR, USA) on one foot at night
only for up to 3 nights in order to estimate periodic leg
movements, and a subset complied and had valid data. In
addition, both CRIC and HCRIC participants completed a
series of validated questionnaires to estimate risk of sleep
apnea, daytime sleepiness and subjective sleep quality.
The activity monitors contain highly sensitive omnidirec-
tional accelerometers that counted movements in 30-s
epochs. Wrist actigraphy has been validated against
polysomnography, demonstrating a correlation for sleep
duration between 0.82 in insomniacs and 0.97 in healthy
subjects (Jean-Louis et al., 1997). We calculated several
measures of sleep using the associated Actiware software.
Sleep duration is the amount of time that is spent sleeping
between sleep onset and final awakening. Sleep fragmenta-
tion is a marker of sleep quality and is an index of
restlessness expressed as a percentage. It is calculated by
summing the percentage of the sleep period that is spent
moving (a 30-s epoch with more than 2 activity counts is
considered moving) and the percentage of the number of
immobile phases (consecutive 30-s epochs with no move-
ment) that last only 1 min or less. Sleep start time is the time
of sleep onset and a marker of the timing of the sleep period.
Sleep start time is calculated by the software as the
beginning of the first 10-min period in which no more than
one 30-s epoch is scored as mobile. From the foot actigra-
phy, we estimated the periodic leg movement index (PLMI),
which is the number of leg movements per hour of sleep,
using the Actiware-PLM software. We then dichotomized this
variable into <15 and ≥15 movements per h.
We administered three validated questionnaires: the Pitts-
burgh Sleep Quality Index (PSQI), the Epworth Sleepiness
Scale (ESS) and the Berlin questionnaire. The PSQI is a
validated 19-item questionnaire assessing subjective sleep
quality over the past month (Buysse et al., 1989). Scores
range from 0 to 21, and a score greater than 5 indicates poor
subjective sleep quality. The ESS is an eight-item question-
naire assessing daytime sleepiness (Johns, 1991, 1992).
Scores range from 0 to 24, and a score greater than 10
indicates excessive daytime sleepiness. Finally, the Berlin
questionnaire is a validated screening tool for sleep apnea
(Netzer et al., 1999). Typically, a participant is identified as
highly likely to have sleep apnea if two of three conditions
were met: (1) persistent snoring symptoms; (2) persistent
daytime dysfunction or sleepiness; or (3) obesity or hyper-
tension. However, because hypertension was present in 95%
of this sample, we used only the ‘persistent snoring symp-
toms’ as an indicator of sleep apnea risk.
Covariates
Covariates used in these analyses include age, sex, race/
ethnicity, body mass index (BMI), current smoker, alcohol
use, and fasting glucose level or presence of diabetes. Four
racial/ethnic groups were examined: non-Hispanic white;
non-Hispanic black; Hispanic/Latino; and other race or
ethnicity. BMI (kg m2) was calculated using measured
height and weight. Participants were asked if they were a
current smoker (yes/no) and if they consumed alcohol (yes/
no). Fasting blood samples were obtained at the clinic
examination and levels of glucose were measured. The
presence of diabetes was defined as fasting glucose
≥126 mg dL1, random glucose ≥200 mg dL1, or use of
insulin or antidiabetic medication.
Statistical analysis
For descriptive analyses, we calculated means and standard
deviations for continuous variables and the percentages for
the categorical variables. We examined the distribution of our
outcome measures, and PCR was log transformed due to a
skewed distribution. Thus, the regression coefficients are
interpreted as percent change per unit increase in the sleep
measure. To test for associations between the sleep mea-
sures and the outcome measures, eGFR and PCR, we used
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separate linear regression models for each outcome and
each sleep measure. Covariates in these initial models
included age, race, sex, BMI, study site (Chicago or Ohio),
systolic blood pressure and fasting glucose. In addition,
because there have been reports of a U-shaped association
between renal function and sleep duration (Lin et al., 2017),
we added a quadratic term for sleep duration to the sleep
duration models. For the illustrations, we calculated the
quartiles for sleep duration, sleep fragmentation and sleep
start time, and calculated the marginal means for eGFR and
PCR for each quartile from regression models that included
the covariates. The mean PCR in these figures was back-
transformed from the natural log used in the regression
models. Finally, we created interaction terms between the
presence of diabetes and each sleep measure as continuous
variables, and between sex and each sleep measure to see if
the associations between sleep and kidney function varied
either between those with and without diabetes or between
men and women. All analyses were conducted using Stata
SE v14 (StatCorp, College Station, TX, USA).
RESULTS
Sixty-eight participants developed ESRD prior to the sleep
assessment and therefore were excluded from these
analyses (Fig. 1). In addition, we excluded participants
missing key data and who had an eGFR<10 or
>80 mL min1 1.73 m2. Our final sample size was 432
patients. The description of the sample is presented in
Table 1. The average age was approximately 60 years and
61% of the sample was obese (BMI≥30 kg m2). Almost half
of the participants were women, and half of the sample had
diabetes. On average, these patients slept for 6.5 h per night,
but this ranged from about 2 h per night to 10 h per night.
Patients went to bed at 23:30 hours on average. Of those
with foot actigraphy, 20% had a PLMI at or above 15
movements per h. Nearly two-thirds of the participants had
PSQI scores above the clinical threshold for poor sleep
quality (score >5), and more than 25% had ESS scores
above the clinical threshold for excessive daytime sleepi-
ness. Approximately one-quarter of the sample had persis-
tent snoring. Furthermore, 80% of participants qualified for at
least one of the following: poor subjective sleep quality
(PSQI > 5); excessive daytime sleepiness (ESS > 10); or
persistent snoring.
Many of the sleep measures were correlated, albeit only
weakly or modestly. For example, shorter sleep duration was
associated with greater sleep fragmentation (r = 0.39,
P < 0.001) and later sleep start time (r = 0.36,
P < 0.001). Higher PLMI was associated with greater sleep
fragmentation (r = 0.28, P < 0.001). Higher PSQI scores
were associated with greater sleep fragmentation (r = 0.16,
P = 0.001), but not with sleep duration or sleep timing (both
P > 0.05). Greater subjective sleepiness was associated with
shorter sleep duration (r = 0.30, P < 0.001), greater sleep
fragmentation (r = 0.16, P < 0.001) and later sleep timing
(r = 0.13, P = 0.006).
Association between sleep and eGFR
Figure 2 presents the adjusted means of eGFR for the
quartiles of sleep duration, sleep fragmentation and sleep
timing. Results from multivariable linear regression analyses
predicting eGFR are presented in Table 2. Lower eGFR was
associated with shorter sleep duration (1.1 mL min1∙1.73
m2 per hour less sleep), greater sleep fragmentation
(2.6 mL min1 1.73 m2 per 10% higher sleep fragmenta-
tion) and later sleep timing (0.9 mL min1∙1.73 m2 per
hour later). Subjective sleep quality, subjective sleepiness,
PLMI and persistent snoring were not associated with eGFR.
The quadratic term for sleep duration was not significant
(P = 0.30), indicating the absence of a U-shaped association
between sleep duration and eGFR.
Association between sleep and PCR
Figure 2 also presents the unadjusted associations between
the distribution of PCR and the quartiles of sleep duration,
sleep fragmentation and sleep timing. Median PCR was
significantly higher in those with greater sleep fragmentation,
but there was no significant association between PCR and
sleep duration or sleep timing quartiles. In the linear regres-
sion models (Table 2), PCR was only associated with greater
N = 537 initially
recruited
N = 469
Excluded 68 with 
ESRD by time of sleep 
assessment
N = 455
Excluded 14 without 
wrist actigraphy data
N = 439






7 Excluded eGFR<10 
or >80 ml/min/1.73 m2
Figure 1. Consort diagram.
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sleep fragmentation (approximately 28% higher PCR per
10% higher sleep fragmentation). Habitual sleep duration, the
quadratic term for sleep duration, sleep start time, PLMI,
subjective sleep quality, sleepiness and persistent snoring
were not associated with PCR.
We examined whether the associations between the
measures of sleep and the measures of kidney function
varied by diabetes status or sex by testing interaction terms
in each of the models. The interaction term between diabetes
and PLMI was considered significantly associated with eGFR
and lnPCR (P < 0.10). Thus, stratified analyses were per-
formed for these models. Among patients with CKD without
diabetes, having a PLMI ≥ 15 events per h was associated
with lower eGFR (beta = 3.8 mL min1 1.73 m2, P = 0.2,
n = 154) and a higher PCR (approximately 28% higher,
P = 0.36, n = 141), although neither association was signif-
icant. Among patients with CKD with diabetes, having a
PLMI ≥ 15 events per h was associated with higher eGFR
(beta = 4.0 mL min1 1.73 m2, P = 0.1, n = 136) and
lower PCR (approximately 63% lower, P = 0.07, n = 126),
but neither association reached statistical significance. The
diabetes interaction terms in all other models were not
significant, and none of the interaction terms with sex was
significant (all P > 0.10).
DISCUSSION
In this sample of patients with pre-dialysis CKD, greater sleep
fragmentation was associated with worse kidney function, as
represented by both eGFR and the urine PCR. Shorter sleep
duration and later sleep timing were also associated with
lower eGFR but not PCR. Subjective sleep quality, sleepi-
ness and persistent snoring (a symptom of sleep apnea)
were not associated with the kidney function measures.
Our study found that reduced sleep quality, as represented
by greater sleep fragmentation, was associated with reduced
eGFR and increased PCR. Experimentally induced sleep
fragmentation in young healthy adults significantly reduced
insulin sensitivity, impaired glucose metabolism and attenu-
ated nocturnal blood pressure dipping (Sayk et al., 2010;
Stamatakis and Punjabi, 2010; Tasali et al., 2008), which are
risk factors for the development of diabetes and hyperten-
sion. Diabetes and hypertension are, in turn, major risk
factors for the development of CKD (Centers for Disease and
Prevention, 2007). Further, experimental sleep fragmentation
led to a 14% increase in cardiac sympathovagal balance,
suggesting a shift toward higher sympathetic activity (Tasali
et al., 2008). If sympathetic nervous activity is elevated due
to habitual sleep fragmentation, then this could impair kidney
Table 1 Description of key characteristics among the CRIC sleep study cohort
Variable Total n Mean (standard deviation) or n (%) Range
Demographics
Age (years) 432 59.7 (10.4) 23–79
BMI (kg m2) 432 33.7 (9.2) 17.6–111.8
Women (n, %) 432 208 (48.2%)
Race/ethnicity 432
Non-Hispanic white (n, %) 152 (35.2%)
Non-Hispanic black (n, %) 137 (31.7%)
Hispanic/Latino (n, %) 135 (31.3%)
Other (n, %) 8 (1.9%)
Current smoker (n, %) 432 57 (13.2%)
Alcohol use (n, %) 432 226 (52.3%)
Diabetes (n, %) 432 218 (50.5%)
Fasting glucose (mg dL1) 432 119.9 (57.7) 49–538
Recruited at Chicago site (n, %) 432 255 (59.0%)
Kidney function, glucose and blood pressure
eGFR (mL min1∙1.73 m2) 432 38.3 (14.5) 10.8–79.0
PCR (mcg mg1; median; IQR) 399 0.20 (0.07, 0.81) 0.01–15.6
Systolic blood pressure (mmHg) 432 130.5 (20.1) 71–200.7
Diastolic blood pressure (mmHg) 432 70.6 (12.0) 37.7–121.3
Sleep variables
Sleep duration (h) 432 6.5 (1.4) 1.7–11.2
Sleep fragmentation (% of sleep period) 432 21.1 (9.8) 3.4–82.8
Sleep start (hh:mm) 432 23:32 (1:37) 19:32–8:26
PLMI > 15 events per h 290 59 (20.3%)
PSQI score 388 8.1 (4.5) 0–21
PSQI > 5 (poor sleep quality) (n, %) 256 (66.0%)
ESS 420 7.9 (4.9) 0–24
ESS > 10 (excessive sleepiness) (n, %) 110 (26.2%)
Persistent snoring (n, %) 364 90 (24.7%)
BMI, body mass index; eGFR, estimated glomerular filtration rate; ESS, Epworth Sleepiness Score; IQR, inter-quartile range; PCR, protein to
creatinine ratio; PLMI, periodic leg movement index; PSQI, Pittsburgh Sleep Quality Index.
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<5.5 h 5.5-6.5 h 6.5-7.3 h 7.3-10.0 h
Sleep Duration Quartile
<5.5 h 5.5-6.5 h 6.5-7.3 h 7.3-10.0 h
<14.3% 14.4-19.8% 19.9-26.7% >26.7%
Sleep Fragmentation Quartile
<14.3% 14.4-19.8% 19.9-26.7% >26.7%
Sleep Fragmentation Quartile
Sleep Start Quartiles
<22:30 22:30-23:23 23:24-0:14 >0:15
Sleep Start Quartiles
<22:30 22:30-23:23 23:24-0:14 >0:15







Figure 2. Mean estimated glomerular filtration rate (eGFR) and protein to creatinine ratio (PCR) levels over the quartiles of sleep duration, sleep
fragmentation and sleep timing adjusted for age, race, sex, body mass index (BMI), study site, systolic blood pressure and fasting glucose. PCR
values have been back-transformed from ln(PCR) used in regression analyses. Error bars represent 95% CI from the regression analysis.
Table 2 Results from seven separate linear regression models predicting eGFR (mL min1 1.73 m2; n = 405) and PCR*
eGFR (mL min1 1.73 m2) ln(PCR)
Beta (95% CI, P-value) Beta (95% CI, P-value)
1. Sleep duration (per hour of sleep) 1.1 (95% CI: 0.1, 2.2, P = 0.03) 0.07 (95% CI: 0.18, 0.04, P = 0.2)
2. Sleep fragmentation (per 10%) 2.6 (95% CI: 4.0, 1.1, P < 0.001) 0.28 (95% CI: 0.13, 0.44, P < 0.001)
3. Sleep start time (per hour later) 0.9 (95% CI: 1.7, 0.01, P = 0.05) 0.04 (95% CI: 0.05, 0.13, P = 0.4)
4. PLMI ≥ 15 events per h 0.1a (95% CI: 4.1, 3.9, P = 0.9) 0.21b (95% CI: 0.65, 0.23, P = 0.4)
5. PSQI score 0.03c (95% CI: 0.4, 0.3, P = 0.9) 0.005d (95% CI: 0.03, 0.04, P = 0.8)
6. ESS 0.06e (95% CI: 0.2, 0.3, P = 0.7) 0.02f (95% CI: 0.01, 0.05, P = 0.2)
7. Persistent snoring 1.7g (95% CI: 1.5, 4.9, P = 0.3) 0.14h (95% CI: 0.19, 0.47, P = 0.4)
eGFR, estimated glomerular filtration rate; ESS, Epworth Sleepiness Scale; PCR, protein to creatinine ratio; PLMI, periodic leg movement
index; PSQI, Pittsburgh Sleep Quality Index.
*Adjusting for age, race, sex, BMI, current smoking, alcohol use (yes/no), systolic blood pressure, fasting glucose and study site.
an = 290; bn = 267; cn = 388; dn = 356; en = 420; fn = 387; gn = 336; hn = 322. Bold = p<=.05.
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function (Masuo et al., 2010). Unfortunately, previous exper-
imental studies that manipulated sleep duration or quality
have not examined effects on kidney function measures. One
other observational study did use actigraphy and estimated
sleep fragmentation (Agarwal and Light, 2011). They found
no association between sleep fragmentation and eGFR;
however, this analysis included only 27 patients with CKD.
A bidirectional relationship between sleep duration and
quality and kidney function is possible. Only a few studies
have documented sleep quality and duration in CKD prior to
kidney failure. Evidence suggests that sleep disturbances in
CKD could be a precursor of the more severe sleep
disturbances described in ESRD (Turek et al., 2012). Studies
that used actigraphy reported that individuals with ESRD had
more disturbed sleep than individuals with CKD (Agarwal and
Light, 2011; Barmar et al., 2009). Elevated sympathetic
nervous system activity can lead to fragmented sleep and,
conversely, fragmented sleep is associated with activation of
the sympathetic nervous system. This bidirectional relation-
ship could constitute a vicious circle where sleep problems
and reduced kidney function enhance one another.
The finding that later sleep timing is associated with kidney
function is a novel discovery and it may be related to
circadian rhythms. A possible explanation for the association
between sleep timing and kidney function is circadian
misalignment between endogenous clocks. Circadian
misalignment can arise when behaviours such as sleep and
meals occur at times that are not in synchrony with our
endogenous clocks, and therefore key organ systems do not
respond properly or work efficiently. Circadian clocks in renal
cells seem to play an important role in the regulation of fluid
levels and blood pressure homeostasis (Tokonami et al.,
2014), thus if there is desynchrony between the circadian
rhythms in the kidney and behaviours such as sleep, it is
possible that disturbances in kidney function could occur. An
additional possible explanation for the association between
later sleep timing and worse kidney function involves mela-
tonin release. Melatonin is a hormone secreted predomi-
nantly by the pineal gland and this secretion is inhibited by
light. People who stay up later will be exposed to artificial light
at night, and because light suppresses melatonin, melatonin
levels may be lower in later sleepers. Melatonin has
antioxidant properties and administration of melatonin pro-
tected kidney allografts from ischaemia/reperfusion injury-
induced renal dysfunction and tubular injury in an animal
model (Li et al., 2009). A recent study in obese mice (Ob/Ob)
found that melatonin administration was associated with
beneficial changes in the renal proximal convoluted tubules,
which suggests that melatonin may be protective against
renal morphological damage and dysfunction due to obesity
(Stacchiotti et al., 2014).
The strengths of this study include the objective estimates
of sleep duration, quality and timing, the large and ethnically
diverse sample. There are a few limitations to note, however.
This study did not have an objective measure of obstructive
sleep apnea (OSA), and OSA may be associated with worse
kidney function in patients with CKD (Pierratos and Hanly,
2011), although not all studies have observed these asso-
ciations (Fornadi et al., 2014). While we did use a validated
screening tool to identify patients with persistent snoring, a
major symptom of sleep apnea, it is possible that the
prevalence of apnea was underestimated. Previous epidemi-
ological data suggested that year-to-year variability in sleep
duration and quality is quite low in middle-aged adults
(Knutson et al., 2007), although the stability of sleep habits
in patients with CKD has not been examined. Finally, the
study design is cross-sectional, and the direction of effect
cannot be determined.
Our study found significant associations between worse
sleep quality, as indicated by greater sleep fragmentation and
reduced kidney function (either lower eGFR or higher PCR).
Shorter sleep duration and later sleep timing were also
associated with worse kidney function as indicated by lower
eGFR. Future research should employ longitudinal and
interventional designs in order to determine whether poor
sleep quality or circadian disruption can impair kidney
function. Physicians treating patients with CKD should
consider inquiring about sleep and possibly sending for
clinical sleep assessment. Importantly, future research
should examine whether improving sleep quality and/or
optimizing circadian rhythms in patients with CKD can slow
CKD progression.
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